Related Experiment Video

Updated: Jun 23, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic

Meidan Ding1, Fangfang Guo1, Ping Lin1

  • 1Affiliated Xinhua Hospital of Dalian University, Dalian, China.

Frontiers in Pharmacology
|June 22, 2026
PubMed

Insights

Isoliquiritigenin (ISL) shows significant anti-ovarian cancer effects by regulating the JAK/STAT pathway. This natural compound is a promising candidate for ovarian cancer targeted and combination therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Ovarian cancer is a leading cause of cancer death in women.
  • The Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signaling pathway plays a crucial role in ovarian cancer progression.
  • Identifying novel therapeutic agents targeting this pathway is essential.

Purpose of the Study:

  • To investigate the mechanism of isoliquiritigenin (ISL) in regulating the JAK/STAT signaling pathway in ovarian cancer.
  • To explore ISL's effects on ovarian cancer cell behavior and the tumor immune microenvironment.
  • To summarize research progress on ISL for ovarian cancer intervention.

Main Methods:

  • Review and integration of cellular, animal, and preclinical studies on ISL treatment for ovarian cancer.
  • Analysis of ISL's modulation of the JAK/STAT pathway.
  • Evaluation of ISL's impact on ovarian cancer cell behavior and the tumor immune microenvironment.

Main Results:

  • Isoliquiritigenin (ISL) demonstrates significant anti-ovarian cancer effects.
  • ISL exerts its effects through multitarget regulation of the JAK/STAT pathway.
  • ISL modulates ovarian cancer cell behavior and the tumor immune microenvironment.

Conclusions:

  • Isoliquiritigenin (ISL) is a promising natural compound for ovarian cancer therapy.
  • ISL offers advantages such as low toxicity and multi-pathway modulation.
  • ISL holds potential for targeted therapy, reversing drug resistance, and combination therapy in ovarian cancer, with value for research and clinical translation.
Keywords:
JAK/STAT signaling pathwayisoliquiritigeninmolecular mechanismsovarian cancertherapeutic potentialtumor immune microenvironment

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...